Add to a list

Inactive Instrument

LOTUS PHARM Stock OTC Bulletin Board

LTUS

US5457151042

Pharmaceuticals

OTC Markets Traded

End-of-day quote OTC Bulletin Board
- ^USD	-

23-07-31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
21-11-26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE

Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	9.74M 8.7M 8.08M 7.36M 13.89M 942M 13.94M 97.3M 38.13M 480M 36.55M 35.76M 1.54B	P/E 2009	3.88x	P/E 2010	4.84x
Enterprise Value	14.38M 12.86M 11.94M 10.88M 20.53M 1.39B 20.6M 144M 56.33M 709M 54M 52.82M 2.28B	EV / Sales 2009	1.02x	EV / Sales 2010	0.95x
Free-Float	99%	Yield 2009 *	-	Yield 2010	-

23-07-31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
21-11-26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE
21-09-28	Lotus Pharmaceuticals : Temasek-backed Vertex expects at least $400 million in new S.E.Asia/India fund	RE
12-05-16	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS from LTUSE	CI
12-04-19	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS.E from LTUS	CI

12-30	Lotus Pharmaceutical Supports Street Medicine Program to Expand Access to Care for Those Most in Need	AQ
25-10-06	Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection	AQ
25-08-12	Lotus Pharmaceutical Achieves New First-Half Record in Revenue for 2025, While Q2 Impacted by FX and Timing of Lenalidomide Sales	AQ
25-02-21	Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis	AQ
24-11-08	Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.83%	+3.19%	+41.49%	+103.56%	1,051B
JOHNSON & JOHNSON	+1.93%	+2.11%	+37.08%	+65.09%	630B
ABBVIE INC.	+1.49%	+5.19%	+19.94%	+85.69%	489B
MERCK & CO., INC.	+2.26%	+0.90%	+69.32%	+40.53%	359B
ROCHE HOLDING AG	+1.45%	+3.50%	+23.29%	+41.62%	344B
NOVARTIS AG	+1.17%	+2.37%	+13.47%	+33.64%	272B
ASTRAZENECA PLC	+0.89%	+1.08%	-6.13%	+9.29%	246B
AMGEN INC.	+1.82%	+2.94%	+42.99%	+52.95%	224B
GILEAD SCIENCES, INC.	+2.77%	+4.44%	+29.01%	+98.99%	187B
Average	+1.62%	+2.53%	+30.05%	+59.04%	422.63B
Weighted average by Cap.	+1.47%	+2.44%	+33.36%	+69.01%

	2009	2010
Net sales	57.82M 51.68M 47.99M 43.72M 82.53M 5.6B 82.81M 578M 226M 2.85B 217M 212M 9.15B	72.7M 64.98M 60.33M 54.97M 104M 7.04B 104M 727M 285M 3.59B 273M 267M 11.51B
Net income	16.43M 14.69M 13.64M 12.43M 23.45M 1.59B 23.53M 164M 64.36M 810M 61.7M 60.35M 2.6B	14.42M 12.89M 11.97M 10.91M 20.59M 1.4B 20.66M 144M 56.5M 711M 54.16M 52.98M 2.28B
Net Debt	5.29 4.73 4.39 4 7.56 512.34 7.58 52.91 20.73 261.09 19.88 19.44 838	4.65 4.15 3.86 3.51 6.63 449.71 6.65 46.44 18.2 229.18 17.45 17.07 735.56

LOTUS PHARM Stock OTC Bulletin Board

Stocks

LTUS

US5457151042

Pharmaceuticals

Valuation: LOTUS PHARM

Latest news: LOTUS PHARM

Press Releases: LOTUS PHARM

Managers and Directors: LOTUS PHARM

Generic Pharmaceuticals

Financials

Company Profile